CME/CPE/CNE On Demand Library
A Multidisciplinary Expert Forum on Postoperative Nausea and Vomiting
CME/CPE/CNE certified multimedia CD featuring expert panel discussions and 3-D mechanism of action animations
Release Date: December 15, 2009
Expiration Date: December 16, 2010
Estimated Time To Complete Activity: 1 hour 35 minutes
Target Audience
This activity has been designed to meet the educational needs of anesthesiologists, nurse anesthetists, postoperative nurses, perianesthesia nurses, physician assistants, nurse practitioners, and health system pharmacists involved in the care of postsurgical patients.
Purpose
To educate healthcare professionals on prophylaxis and treatment of postoperative nausea and vomiting (PONV)/postdischarge nausea and vomiting (PDNV).
Program Overview
Each year, approximately 75 million Americans are affected by PONV/PDNV, which remains the most common postoperative complication. It is the most frequently reported fear about elective surgeries, and is considered more debilitating than postoperative pain. Not only does PONV/PDNV have a significant impact on patient quality of life, but it could also lead to subsequent complications such as aspiration and wound dehiscence. These concerns persist despite the availability of new antiemetic agents with proven efficacy, multimodal interventions, better understanding of patient risk stratification, and the development of several consensus-based clinical practice guidelines.
This Web-based certified educational activity will bring together a multidisciplinary panel of PONV/PDNV thought leaders to review the state of PONV/PDNV prophylaxis and treatment. A review of central and peripheral neurotransmitters that stimulate nausea/vomiting and the antiemetics designed to antagonize such signaling will be described in 3-D video animations. Other topics presented will include identified risk factors, clinical practice guidelines, assessment, and patient education. A substantial portion of the program will be dedicated to group discussion regarding how consensus-based PONV/PDNV guidelines can be better adopted in community clinical practice.
An archive of this forum will be posted on IMERonline.com. A CE-certified CD of this program will be made available as a professional resource, which will include the library of 3-D video animations and forum discussion.
Learning Objectives
Upon completion of this program, participants should be better able to:
- Define the scope of PONV/PDNV incidence
- Identify the central/peripheral neurotransmitters that stimulate nausea/vomiting
- Describe PONV/PDNV risk factors based on currently available level of evidence
- Differentiate the mechanisms of action among the various antiemetic classes
- Compare the available PONV/PDNV consensus-based clinical practice guidelines
- Identify potential practice barriers to implementation of consensus-based PONV/PDNV clinical practice guidelines
Safeguards Against Commercial Bias
IMER and PIM affirm that the content and format of its CME activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, IMER and PIM employ several strategies to ensure the absence of commercial bias, including but not limited to review of all planned content for CME activities jointly sponsored by IMER and PIM to ensure adherence to the Accreditation Council for Continuing Medical Education’s content validation statements and resolution of any actual or perceived conflict of interest that exist. We employ three metrics as we review materials:
1. Fair balance
- Recommendations or emphasis must fairly represent and be based on a reasonable and valid interpretation of the information available on the subject matter
- No single product or service is overrepresented when other equal competing products or services are available for inclusion
2. Scientific objectivity of studies mentioned in the materials or used as the basis for content
3. Appropriateness of patient care recommendations made to learners
Media
Hardware and Software Requirements
IMER requires Microsoft Internet Explorer version 7.0 or higher, Firefox version 2.0 or higher, or Safari version 2.0 or higher. Certain educational activities may require additional software and hardware to view multimedia presentations or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player. Hardware may require CD-ROM and DVD-ROM optical drive.
| Jointly Sponsored by: | |
 |
 |
| This activity is supported by an independent educational grant from Eisai, Inc. | |
Series chairperson
Christian C. Apfel, MD, PhD (Faculty Presenter)
University of California, San Francisco
Faculty Presenters
Julie Golembiewski, PharmD
University of Illinois at Chicago
Joseph F. Burkard, CRNA, DNSc
University of San Diego
Denise O’Brien, MSN, RN, ACNS-BC, CPAN, CAPA, FAAN®
University of Michigan Health System
ACCREDITATION STATEMENT
Physician Continuing Education
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and Institute for Medical Education and Research (IMER). PIM is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Postgraduate Institute for Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physician Assistant Education
AAPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
Pharmacist Continuing Education
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education
Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (0.20 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - 809-999-09-112-H01-P)
GNA/ANCC
This educational activity for 2.0 contact hours is provided by IMER. IMER is an approved provider of continuing nursing education by the Georgia Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
CaBRN
IMER is approved by the California Board of Registered Nursing, Provider Number 14763 for 2.4 contact hours.
Type of Activity
Knowledge and application
A statement of credit will be issued only upon receipt of a completed activity evaluation form.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Christian C. Apfel, MD, PhD, reported a financial interest/relationship or affiliation in the form of: Contracted Research, Acacia Pharma Ltd., Bristol-Myers Squibb Company, Eisai, Inc., MGI Pharma, Inc.; Consultant/Financial Support, Acacia Pharma Ltd., Eisai, Inc., Merck & Co., Inc.
Denise O’Brien, MSN, RN, ACNS-BC, CPAN, CAPA, FAAN®, has no real or apparent conflicts of interest to report. Joseph F. Burkard, CRNA, DNSc, has no real or apparent conflicts of interest to report.
Julie Golembiewski, PharmD, has no real or apparent conflicts of interest to report.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Melissa Gomez, BSN, RN, OCN®, reported a financial interest/relationship or affiliation in the form of: Speakers’ Bureau, Eli Lilly and Company (spouse), Genentech BioOncology (spouse); Contracted Research, Merck & Co., Inc. (spouse), Roche Laboratories, Inc. (spouse), Gemin X (spouse), Tragara Pharmaceuticals, Inc. (spouse).
The following IMER planners and managers, Michael Bramwell; Lourdes Briz, BS; Timothy J. DiChiara, PhD; Ninotchka Doleyres, MPH; Dorothy Dulko, PhD, RN, AOCNP-C®; Elisheva Hertz, BSN, RN, OCN®; Madelyn T. Herzfeld, BSN, RN, OCN®; Davecia Ragoonath-Cameron, MS; Matthew Weeks, BA, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following PIM planners and managers, Linda Graham, RN, BSN, BA; Jan Hixon, RN, BSN, MA; Trace Hutchison, PharmD; Julia Kirkwood, RN, BSN; and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.